32 results about "Hemangioma" patented technology

The invention relates to a spring ring releasing structure and a spring ring system. The spring ring releasing structure comprises a pushing rod, a notch elastic piece located in the pushing rod and a traction wire connected with the notch elastic piece. The notch elastic piece is provided with a notch used for clamping a spring ring ball head, and the outer side wall of the notch elastic piece abuts against the inner wall of the pushing rod. A releasing groove is formed in the far end of the pushing rod, when the outer side wall of the notch elastic piece abuts against the groove bottom of the releasing groove, the caliber of the notch is larger than the diameter of the spring ring ball head, and when the outer side wall of the notch elastic piece abuts against the inner wall, outside the releasing groove, of the pushing rod, the caliber of the notch is smaller than the diameter of the spring ring ball head. The defects that an existing spring ring release structure limits the filling effect of a spring ring in hemangioma and the tube kicking phenomenon is likely to be caused are overcome, the embolism precision is improved in a free torsion air-finding connection mode, the fracture risk is reduced through low-pressure filling, meanwhile, the reliability of mechanical release is kept, and the safety of the embolism is improved. The method is a targeted upgrade of an interventional embolism spring ring release technology.

The invention discloses a positioning and delimiting method and system for a cortex pathological focus based on an intracranial electroencephalogram signal. The method comprises the following steps: constructing an individualized three-dimensional navigation model; obtaining an original intracranial electroencephalogram signal; generating a plurality of representative segments according to the original intracranial electroencephalogram signals; analyzing the original intracranial electroencephalogram signal and the plurality of representative segments so as to obtain a network analysis core index; generating a fusion type three-dimensional brain model according to the network analysis core index and the individualized three-dimensional navigation model; generating a space-time three-dimensional electroencephalogram model and an electrophysiology functional area distribution diagram according to the fused three-dimensional brain model and the network analysis core indexes; and according to the space-time three-dimensional electroencephalogram model and the electrophysiology functional area distribution map, generating accurate electrophysiology positioning and delimiting information of the cortical pathological focus. According to the invention, accurate electrophysiological delimitation of intra-operative cortical pathological lesions (glioma, hemangioma, focal cortical dysplasia and the like) is realized.

The utility model discloses a device for reducing hardener overflow in maxillofacial hemangioma cavity injection, and the device comprises a first clamping part which comprises a first hand-held part and an annular pressing ring arranged at the end part of the first hand-held part, and a second clamping part which comprises a second hand-held part and an annular pressing ring arranged at the end part of the second hand-held part, the second clamping part comprises a second handheld part and a matched pressing part arranged at the end part of the second handheld part; the first clamping part is connected with the second clamping part through the hinge seat; the second handheld part is provided with a tooth positioning arc-shaped plate for allowing the arc-shaped positioning plate to penetrate through, and one end of the tooth positioning arc-shaped plate is fixedly connected with the first clamping part; the elastic sheet is arranged between the first handheld part and the second handheld part, and one end of the elastic sheet is fixed on the second handheld part through a screw; and the locking plate is used for locking the annular pressing ring and the matched pressing part at a preset opening and closing angle. The medicine is effectively prevented from overflowing in the injection process, so that the treatment effect is improved, and the potential risk of the medicine to other parts of a patient is reduced.

The invention discloses a disposable sclerosis injection device special for hemangioma or cyst, and belongs to the technical field of medical instruments. A first connector of the first three-way pipe is connected with an extension pipe of the puncture needle or connected with the puncture needle through a first extension pipe; the first injector is connected with a second connector of the first three-way pipe through a second extension pipe; a first end of the third extension pipe is connected with a third interface of the first three-way pipe; the second end of the third extension tube is connected with the second injector; or, the second end of the third extension tube is connected with the first connector of the second three-way tube, the second connector of the second three-way tube is connected with the third injector, and the third connector of the second three-way tube is connected with the fourth injector. According to the invention, different vein puncture needles are flexibly assembled into the sclerosis injection device special for hemangioma or cyst and suitable for different application scenes, so that cyst suction, radiography and free sclerosing agent injection can be realized.

The present application relates to a kind of hemangioma occlusion device, hemangioma occlusion treatment device and hemangioma occlusion system, hemangioma occlusion device includes mesh expansion structure and guide structure, the mesh expansion structure has from the unwinding state of spiral shape around from distal end to proximal end and the compressed state for being delivered from inside blood vessel to hemangioma;At least a part of the guide structure is arranged in the lumen of mesh expansion structure, and when the mesh expansion structure is in spiral shape, at least a part of the guide structure is unwound in the lumen of mesh expansion structure in spiral shape.The present application has the advantages of preventing hemangioma rupture, preventing vascular embolism, improving the coverage of tumor neck, promoting the formation of intratumoral thrombus, accelerating hemangioma embolism and the like while realizing stable and compliant tamponade.

The present invention provides an implantable medical device, comprising a spring coil structure and a connecting structure, wherein the connecting structure comprises an anti-unraveling wire, a soft wire, a first connecting member housed inside the proximal end of the spring coil structure, and a second connecting member disposed outside the proximal end of the spring coil structure, wherein one end of the anti-unraveling wire is connected to the distal end of the spring coil structure, and the other end of the anti-unraveling wire is connected to the first connecting member, one end of the soft wire is connected to the first connecting member and the other end is connected to the second connecting member, and the length of the soft wire extending into the spring coil structure varies with the length of the spring coil structure. When the spring coil structure of the present invention is released into a hemangioma, the soft wire is pulled into the spring coil structure, and the length of the soft wire extending into the spring coil structure varies with the length of the spring coil structure, thereby compensating for the length of the anti-unraveling wire, placing the anti-unraveling wire and the spring coil structure in a relaxed state, ensuring the flexibility of the spring coil structure, and preventing the hard spring coil structure from bursting the hemangioma.

This invention discloses a medical image processing method, device, medium, and product, relating to the field of medical image processing technology. The method includes: acquiring the segmentation results of hemangioma and tumor-bearing vessels in a scanned image of a target vessel; determining a first point set for the hemangioma based on the hemangioma segmentation results; determining a second point set for the tumor-bearing vessels based on the tumor-bearing vessel segmentation results; determining a bidirectional neighboring point set for the first and second point sets, each bidirectional neighboring point set including at least three non-collinear pixels; determining a plane equation for the tumor diameter plane based on the bidirectional neighboring point set; determining the intersection points of the plane containing the plane equation with the first and second point sets, and using the plane enclosed by all intersection points as the tumor diameter plane. The technical solution provided by this invention solves the technical problem of slow speed in existing tumor diameter plane determination methods, improving the speed of tumor diameter plane determination.

The invention discloses timolol maleate gel emplastrum and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The gel paste comprises timolol maleate, a gel skeleton, a cross-linking agent, a cross-linking regulator, a filler, a penetration enhancer, a tackifier, a humectant, a pH regulator, a preservative and purified water. The preparation method comprises the following steps: preparing an oil phase; preparing the medicine and the water-soluble auxiliary materials into a solution; the tackifier adopts methyl acrylate / acrylic acid 2-ethylhexyl copolymer resin emulsion as a single phase; mixing the oil phase with the solution and the tackifier to obtain uniform gel paste with better ductility; and uniformly coating the paste on a backing layer, covering with a protective layer, and packaging to obtain the timolol maleate gel emplastrum. Through optimized prescription composition and process, the preparation has the characteristics of stable drug content and good skin adhesion, can realize continuous transdermal release of drugs, and is especially suitable for long-term safe treatment of infantile hemangioma.

The present application belongs to the technical field of diabetic retinopathy lesion detection, and particularly relates to a diabetic retinopathy lesion detection method based on adaptive multi-label recognition, which comprises: acquiring multi-phase image data of FFA images of a patient; using a "16-tile input" method to combine and splice each group of 10 time-series FFA images; building a D-LAM model composed of a class-adaptive mapping module, a label-specific decoding module and a smooth focus loss function; using the processed FFA image data set to train and verify the model, and finally realizing automatic recognition of different types of lesions on the test set. The method significantly improves the recognition ability of micro-lesions such as microangioma, effectively handles the complex semantic correlation between multi-labels, and effectively assists doctors in identifying diabetic retinopathy, thereby improving the recognition efficiency and accuracy of diabetic retinal lesions.

The invention relates to a medicament or method for topically treating hemangioma, comprising, or administering, Propranolol and Fosinopril in a molar ratio of 2 to 0.9 - 1.3 respectively. The invention also relates to the use of Propranolol and Fosinopril in the manufacture of a medicament for topical administration to a human patient for treating hemangioma, where the Propranolol and Fosinopril are in a molar ratio of 2 to 0.9 - 1.3.

The application discloses application of coccinellin in antitumor drugs and the drugs, wherein the coccinellin has a molecular formula of C 14 H 10 N2O5, and the tumor includes at least one of colorectal cancer, pancreatic cancer, lung cancer, liver cancer, gastric cancer, thyroid cancer, kidney cancer, bladder cancer, ovarian cancer, cervical cancer, breast cancer, myeloma, hemangioma and central nervous system tumor. The antitumor mechanism of the coccinellin is to inhibit KRAS G12D mutant subtype. The coccinellin can effectively inhibit proliferation of various tumor cells, and is expected to be applied to tumor treatment as an antitumor small molecule targeted drug.

The invention relates to the technical field of traditional Chinese medicine preparations, and discloses a traditional Chinese medicine composition for treating skin hemangioma and a preparation method thereof. Comprising the following components in parts by mass: 15-25 parts of salvia miltiorrhiza, 10-20 parts of curcuma zedoary, 12-25 parts of selfheal, 10-15 parts of spina gleditsiae, 8-12 parts of purslane, 6-10 parts of verbena, 6-10 parts of honeycomb, 8-12 parts of wild buckwheat, 8-12 parts of indigo naturalis, 6-10 parts of philippine violet herb, 6-10 parts of lignum dalbergiae odoriferae, 4-8 parts of linseed, 8-12 parts of radix pseudostellariae, 4-8 parts of eclipta, 4-8 parts of black sedge, 4-8 parts of swertia mileensis and 6-8 parts of caulis spatholobi. Through reasonable compatibility of various traditional Chinese medicines, the traditional Chinese medicine composition comprehensively acts on skin hemangioma from the aspects of clearing away heat and toxic materials, promoting blood circulation to remove blood stasis, reducing swelling and removing stasis, reinforcing qi and nourishing blood and the like, can effectively improve symptoms of hemangioma and promote regression of tumor bodies, and is clinically verified to be high in effective rate.

Heterocyclic compounds, their stereoisomers and their pharmaceutically acceptable salts are useful in the treatment of many types of cancers, such as cancers of the breast, prostate, pancreatic, gastric, lung, colon, rectum, esophagus cancer, duodenum, tongue, pharynx, liver, kidney, bile duct, uterine body, cervix, ovaries, urinary bladder, and skin. Other cancers to be treated include brain tumor, neurinoma, clear cell carcinoma, non-small cell lung cancer, small cell lung cancer, hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer, bone tumor, vascular fibroma, glioblastoma, Neuroblastoma, sarcoma, neuroendocrine tumors, retinoblastoma, penile cancer, pediatric solid cancer, renal cell carcinoma, lymphoma, myeloma, leukemia, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, cutaneous T-cell lymphoma (CTCL), multiple myeloma (MM), myeloproliferative neoplasms (MPN), Myelodysplastic syndrome (MDS), polycythemia vera (PV), essential thrombocythemia, essential thrombocytosis (ET), and myelofibrosis (MF), and also including their metastases.

The utility model discloses a flexible clasp nail for blood purification buttonhole puncture, which adopts a flexible sleeve made of a flexible material, so that the contact hardness between the clasp nail and the skin of a patient is reduced, the patient cannot feel hard foreign matters when the clasp nail intervenes into the human body, and the discomfort of the patient is relieved; the comfort level and the treatment quality of the patient are improved; the flexible material can better adapt to the blood vessel structure of a patient, the puncture failure condition caused by blood vessel movement or insufficient elasticity of the blood vessel wall is reduced, the occurrence of hemangioma is reduced, the puncture failure rate is reduced, and therefore the treatment effect is guaranteed. The cramp main body is made of the hard material, so that the stability and the supporting property of the cramp when the cramp is inserted into the scar tunnel are ensured, the condition that the cramp cannot be inserted into the scar tunnel of the vein tube wall due to excessive softness is prevented, and the risks of mistaken penetration and needle falling are reduced. Due to the design of the handheld part of the clasp nail body, medical staff can hold and operate the clasp nail conveniently, the puncture process is simplified, and the working efficiency is improved.

The application belongs to the technical field of biological medicine, and discloses a kind of high-efficiency vascular endothelial cell targeting vesicle system, which is prepared by hemangioma stem cell-derived exosome HemSCs-Exos and bone marrow mesenchymal stem cell-derived apoptotic body BMSCs-ABs, and the application further discloses a preparation method of the vesicle system and its application in promoting endothelial cell proliferation and migration. Unlike existing targeted modification, the ingenious targeting relationship between BMSCs-ABs and endothelial cells in the application belongs to the combination of non-special modification, which is simple and efficient. The fusion between double EVs has the characteristics of "1+1>2", which not only retains the therapeutic components of HemSCs-Exos and BMSCs-ABs, but also has a significant cell-specific distribution after fusion. The fusion method is simple and stable.

The invention relates to the field of biomedical engineering, and discloses a hemostatic agent for jaw central hemangioma hemorrhage and a preparation method and application thereof. The invention is as follows: chitosan powder and organic weak acid are added into organic alcohol to react, so as to prepare chitosan weak acid salt, and then the chitosan weak acid salt is mixed with carboxymethyl chitosan in proportion to obtain the hemostatic agent of the invention. The hemostatic agent of the invention has good fluidity and plasticity. When applied to the hemostasis of jaw central hemangioma hemorrhage, the hemostatic agent of the invention can quickly reach the point of jaw central hemangioma hemorrhage without any stimulation and damage to the tissue. In addition, the hemostatic agent of the invention can inhibit the growth of bacteria, eliminate cross infection, and is easy to clean and remove. Therefore, the hemostatic agent of the invention can safely and effectively treat the massive hemorrhage of jaw central hemangioma, which is worthy of clinical promotion. At the same time, the hemostatic agent of the invention can also be used for hemostasis of hemorrhage points in tissue cavities with special structures.

The invention relates to the technical field of care solutions, and discloses a care solution for treating skin hemangioma and a preparation method thereof, the care solution comprises the following components by mass: 10-26 parts of an active component, 1-5 parts of sodium hyaluronate, 5-15 parts of glycerin, 3-10 parts of propylene glycol, 0.5-3 parts of azone, 0.1-1 part of menthol, 0.5-2 parts of phenoxyethanol and 0.1-0.5 part of ethylhexylglycerin. The care solution capable of inhibiting blood vessel growth and promoting cell apoptosis is obtained by specially limiting active components, and substances with anti-inflammatory and repairing effects are also added, so that the efficacy of the care solution is improved.

The application provides a post-hemangioma operation treatment device, which comprises a shell, a slidable and rotatable driving wheel arranged on the shell and protruding out of the shell, a liftable lifting frame arranged in the shell, a driving mechanism connecting the lifting frame and the driving wheel to convert the rotation of the driving wheel into driving the lifting frame to lift, a blade detachably arranged at the end of the lifting frame, mounting frames arranged on both sides of the shell, squeeze assemblies hinged at the ends of the mounting frames, and a linkage mechanism connecting the squeeze assemblies and the driving wheel to convert the sliding of the driving wheel into driving the two groups of squeeze assemblies to open and close along the hinge points of the squeeze assemblies and the mounting frames. The device can effectively support the blade during the process of picking the post-hemangioma operation blister, can quickly squeeze out the blister liquid and clean it after picking the blister, effectively avoids the blister liquid from flowing onto the skin and solidifying, and improves the working efficiency of the post-hemangioma operation blister treatment.

The invention relates to an embolism assembly and an embolism system for treating hemangioma, the embolism assembly is provided with a far end and a near end which are opposite, the embolism assembly comprises an embolism part, the embolism part is made of shape memory polymer foam, and a threading channel is formed in the embolism part; the near end of the delivery shaft is an operating end, the far end of the delivery shaft is provided with a connecting section, the connecting section is detachably inserted into the threading channel, the connecting section is clamped when the embolism part is intervened and delivered after being loaded, and the connecting section is clamped when the embolism part is released. The connecting section is moved out of the threading channel, and the threading channel is sealed by the plug piece; the blocking net is fixed to the delivery shaft, the blocking net has a compressed state suitable for interventional delivery and a relative unfolded state, the blocking net is located on the near end side of the connecting section in the compressed state, and the blocking net is used for blocking the embolism piece in the unfolded state. Through the structural improvement of the plug part and the mutual cooperation of the plug part and the blocking net, a better positioning effect can be achieved.

The application discloses an anti-CD31 monoclonal nanobody and application thereof, and relates to the technical field of phage display. The anti-CD31 monoclonal nanobody provided by the application is CD31-1040 and CD31-1042; the amino acid sequences of the heavy chain complementarity determining regions CDR1, CDR2 and CDR3 of the monoclonal nanobody CD31-1040 are respectively shown as SEQ ID NO. 1-3; the amino acid sequences of the heavy chain complementarity determining regions CDR1, CDR2 and CDR3 of the monoclonal nanobody CD31-1042 are respectively shown as SEQ ID NO. 6-8. The two camel-derived monoclonal nanobody sequences with high affinity and specific recognition of human CD31 protein can be used for the expression of CD31 on tissues or cells, and further for the assessment of the conditions of various hemangiomas.

The present application relates to a kind of hemangioma occlusion device, hemangioma occlusion treatment device and hemangioma occlusion system;Hemangioma occlusion system includes hemangioma occlusion device and microcatheter;Hemangioma occlusion device includes the main occlusion structure of net tubular shape, main occlusion structure has the unwinding state of plane helix and is used for from inside the vessel delivery to aneurysm compressed state, and the net tube outer diameter of main occlusion structure is uneven, so that the outer diameter distribution of plane helix when main occlusion structure unwinds is uneven;Hemangioma occlusion device is compressed in microcatheter, and after being separated from microcatheter, it can also restore into unwinding state;Hemangioma occlusion treatment device includes hemangioma occlusion device and push rod, push rod is connected to the proximal end of main occlusion structure.The present application is suitable for irregular aneurysm, and the forming effect is good, and it is easier to realize the occlusion of tumor neck.

The invention provides a gene detection kit for molecular diagnosis of hemangioma and vascular malformation and application. Specifically, the invention provides a gene combination for determining molecular diagnosis of hemangioma and vascular malformation, and based on NGS panel + RNAseq gene sequencing, the gene combination for molecular diagnosis of hemangioma and vascular malformation provided by the invention can be applied to all molecular diagnosis and liquid biopsy related to hemangioma and vascular malformation. The correlation between mutation sites and abundance and disease phenotypes is disclosed, so that the method has a relatively great clinical popularization and application prospect.

The present application relates to a kind of embolism device and embolism system, embolism system includes push rod and embolism device, the distal end of push rod is releasably connected with the fixed structure of embolism device, embolism device includes the fixed structure and the axial connection of far-end grid body and near-end grid body in sequence, far-end grid body and near-end grid body are made of two ends closed net tube, and far-end grid body and near-end grid body can be relatively twisted;Wherein: embolism device at least has compression state and unfolded state, and can be switched between compression state and unfolded state;So configure, it can reduce the damage to tumor wall, avoid the risk of proximal herniation into tumor blood vessel, and be applicable to different specifications of hemangioma, expand application range.

The invention belongs to the field of biological detection, and discloses a gene detection panel for detecting hemangioma and vascular malformation and application of the gene detection panel. The invention discloses a gene detection panel for hemangioma and vascular malformation. Comprising the gene detection panel and is used for detecting hemangioma and vascular malformation; an application of the gene detection panel in preparation of a hemangioma and vascular malformation diagnostic reagent or diagnostic kit; the gene detection panel is applied to a device for auxiliary diagnosis of etiology of hemangioma and vascular malformation patients; and the device is used for auxiliary diagnosis of pathogenesis of hemangioma and vascular malformation patients. The gene detection panel disclosed by the invention can efficiently and accurately identify gene mutation related to hemangioma and vascular deformity, can cover wide genes related to hereditary and sporadic vascular deformity, and can provide accurate information for diagnosis, treatment and prognosis evaluation of diseases.

The utility model belongs to the technical field of medical instruments, and relates to a covered stent, an intravascular implantation assembly and a conveying system. The covered stent comprises a stent body and a filling pipe arranged in the stent body, a filling channel is formed in the filling pipe, and an inner cavity of the stent body is communicated with the outer side of the stent body through the filling channel; the covered stent conveying system comprises a covered stent and a covered stent conveyor used for conveying the covered stent. The intravascular implantation assembly comprises a covered stent and a hemangioma cavity implant; the intravascular implant assembly conveying system comprises an intravascular implant assembly and an implant assembly conveyor used for conveying the intravascular implant assembly. Compared with the prior art, the filling channel is reserved in the covered stent, after the covered stent is implanted, the hemangioma cavity implant can be conveyed into the hemangioma cavity through the filling channel so as to fill the hemangioma cavity, operation difficulty and operation risks are reduced, and safety is improved.

The application discloses a method and system for locating and delimiting a cortical pathological focus based on an intracranial electroencephalogram signal. The method comprises the following steps: constructing an individualized three-dimensional navigation model; obtaining an original intracranial electroencephalogram signal; generating a plurality of representative segments according to the original intracranial electroencephalogram signal; analyzing the original intracranial electroencephalogram signal and the plurality of representative segments to obtain network analysis core indexes; generating a fusion three-dimensional brain model according to the network analysis core indexes and the individualized three-dimensional navigation model; generating a space-time three-dimensional electroencephalogram model and an electrophysiological functional area distribution map according to the fusion three-dimensional brain model and the network analysis core indexes; and generating accurate electrophysiological locating and delimiting information of the cortical pathological focus according to the space-time three-dimensional electroencephalogram model and the electrophysiological functional area distribution map. The application realizes accurate electrophysiological delimiting of an intraoperative cortical pathological focus (glioma, hemangioma, focal cortical dysplasia, etc.).

The application provides a method for constructing a hemangioma animal model, and belongs to the field of animal models. The method is to inject hemangioma endothelial cells and hemangioma pericytes into subcutaneous tissues of an animal, and to obtain a hemangioma animal model after 5-30 days. The application successfully constructs a hemangioma animal model based on hemangioma endothelial cells and hemangioma pericytes, the hemangioma animal model has a short construction time, consistent pathological characteristics with those of hemangioma, and can simulate the characteristics of in-vivo hemangioma from proliferation to regression evolution, thereby providing an important animal model carrier platform for in-vitro mechanism research of hemangioma and screening of new targeted drugs.

The invention belongs to the field of biological detection, and discloses a gene detection panel for detecting hemangioma and vascular malformation and application of the gene detection panel. The invention discloses a gene detection panel for hemangioma and vascular malformation. Comprising the gene detection panel and is used for detecting hemangioma and vascular malformation; an application of the gene detection panel in preparation of a hemangioma and vascular malformation diagnostic reagent or diagnostic kit; the gene detection panel is applied to a device for auxiliary diagnosis of etiology of hemangioma and vascular malformation patients; and the device is used for auxiliary diagnosis of pathogenesis of hemangioma and vascular malformation patients. The gene detection panel disclosed by the invention can efficiently and accurately identify gene mutation related to hemangioma and vascular deformity, can cover wide genes related to hereditary and sporadic vascular deformity, and can provide accurate information for diagnosis, treatment and prognosis evaluation of diseases.

The utility model belongs to the technical field of medical tools, in particular to a spring ring device for treating hemangioma, which comprises a spring component, the spring component comprises a support spring, an inner layer spring and a connecting rod, the inner layer spring is sleeved on the inner side of the support spring, one end of the support spring is fixedly connected with the connecting rod, and the other end of the support spring is fixedly connected with the connecting rod. And one end of the connecting rod is fixedly connected to one end of the inner-layer spring. After the supporting spring is connected to the inner side of the movable guide pipe in a sleeved mode, the middle of the supporting spring is extruded through the movable guide pipe on the outer side, the spring assembly is more stable and not prone to falling off in the moving process through extrusion limiting, and after the spring assembly moves to the inner side of a hemangioma subsequently, the spring is ejected out through the ejection guide pipe. The drum-shaped spring on the outer side is supported at the hemangioma after being expanded, the spring placement stability is improved, and the practicability is high; through the arrangement of the inner-layer spring and the outer-layer spring, the blocking effect of the springs on blood flow is improved, and the hemangioma embolism efficiency is improved.

This invention discloses the application of GLPG0187 in combination with propranolol in the preparation of drugs for the treatment or inhibition of hemangiomas. GLPG0187 is an integrin β1 inhibitor, and propranolol is a β-receptor blocker. This invention was validated through CCK8 assays, scratch assays, and tube formation assays. The results showed that, compared with propranolol monotherapy, GLPG0187 (4 nM) combined with propranolol (20-30 μM) could further inhibit the proliferation, migration, and tube formation ability of human hemangioma endothelial cells, demonstrating superior efficacy compared to propranolol monotherapy. This invention addresses the issue that approximately 2.1% of patients treated with propranolol monotherapy for infantile hemangiomas experience side effects such as sleep disturbances, bronchospasm, and hypoglycemia, providing a new combination therapy regimen and offering a new drug option for reducing the clinical dosage of propranolol and minimizing the risk of side effects. This invention identifies a new target for the treatment of hemangiomas, providing new possibilities for hemangioma treatment.